1. Home
  2. SUIG vs IMMX Comparison

SUIG vs IMMX Comparison

Compare SUIG & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sui Group Holdings Limited

SUIG

Sui Group Holdings Limited

N/A

Current Price

$1.21

Market Cap

270.0M

Sector

Finance

ML Signal

N/A

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$7.33

Market Cap

306.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUIG
IMMX
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
270.0M
306.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SUIG
IMMX
Price
$1.21
$7.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$5.75
$13.00
AVG Volume (30 Days)
748.1K
963.5K
Earning Date
03-09-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,608,807.00
N/A
Revenue This Year
$47.71
N/A
Revenue Next Year
$42.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.58
N/A
52 Week Low
$1.13
$1.34
52 Week High
$8.66
$7.73

Technical Indicators

Market Signals
Indicator
SUIG
IMMX
Relative Strength Index (RSI) 29.52 70.04
Support Level $1.17 $6.02
Resistance Level $1.33 $7.04
Average True Range (ATR) 0.13 0.59
MACD -0.02 0.15
Stochastic Oscillator 10.00 96.63

Price Performance

Historical Comparison
SUIG
IMMX

About SUIG Sui Group Holdings Limited

Sui Group Holdings Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: